On August 28, 2025 Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, reported that management is scheduled to present at the following investor conferences in September (Press release, Crescent Biopharma, AUG 28, 2025, View Source [SID1234655981]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.

– Morgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.

A live webcast of each presentation will be available in the Investors section of the Company’s website at View Source, and a replay will be accessible for 90 days.

On August 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) reported that, in accordance with the collaboration development plan, it has received the third clinical development milestone payment of $5 million from Instil Bio, Inc (Nasdaq: TIL, "Instil") as scheduled, in relation to the licensing and collaboration on IMM2510 and IMM27M (Press release, ImmuneOnco Biopharma, AUG 28, 2025, View Source [SID1234655713]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The receipt of this $5 million payment marks significant progress in the clinical development of the collaboration project. It not only reflects ImmuneOnco’s strength in innovative drug research and development but also demonstrates the efficient cooperation between the two parties, providing strong financial support for the further advancement of the project. With the arrival of this milestone payment, the total amount received from the collaboration project has reached as high as $35 million, indicating the rapid progress of the collaboration and the positive and sincere attitude of both parties in their cooperation.

Key Terms of the Licensing Agreement
On August 1, 2024, ImmuneOnco entered into a business development (BD) collaboration worth over $2 billion with Axion Bio, Inc., a wholly-owned subsidiary of Instil Bio, Inc. (formerly known as SynBioTx). Axion Bio, Inc. obtained the rights to develop and commercialize two products, IMM2510 and IMM27M, from ImmuneOnco’s pipeline outside the Greater China region. In addition to retaining the rights to these two products within the Greater China region, ImmuneOnco received an upfront payment and recent payments totaling $50 million, as well as over $2 billion in subsequent development, registration, and commercial milestone payments, and single-digit to low double-digit sales royalties outside the Greater China region.

Clinical Trial Updates
The Phase I clinical study of IMM2510 in Chinese patients with solid tumors has shown positive efficacy signals and good safety, especially in patients with squamous non-small cell lung cancer (SQ-NSCLC) who had previously failed treatment with PD-1 or PD-L1 inhibitors. These results will be presented at the 2025 World Conference on Lung Cancer (WCLC).

The Phase II clinical trial of IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) is recruiting patients smoothly in China. As of July 1, 2025, the overall best objective response rate (ORR) in the evaluable population was 62%, with an ORR of 80% in patients with squamous NSCLC. The safety of this therapy is tolerable and controllable, supporting further clinical development. Plans are underway to initiate a Phase III clinical trial. More relevant research results will be published at future international academic conferences.

A Phase I clinical trial of IMM2510 monotherapy for recurrent/refractory solid tumors is scheduled to be launched in the United States in the second half of 2025.

(The above Phase II clinical data for IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has been previously disclosed by the company.)

Statement from ImmuneOnco’s Founder, Chairman, CEO, and CSO

Dr. Tian Wenzhi, Founder, Chairman, CEO, and CSO of ImmuneOnco, stated: "We are very pleased that our collaboration with Instil Bio has achieved another clinical development milestone. This not only recognizes our strength in innovative drug research and development but also reflects the close cooperation and efficient progress between the two parties. We will continue to work closely with Instil Bio to accelerate the global development of IMM2510 and IMM27M, striving to bring new treatment hopes to cancer patients worldwide as soon as possible. At the same time, ImmuneOnco will continue to be committed to the research and development of innovative drugs, providing more high-quality treatment options for patients globally."

On August 28, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through Al-powered drug discovery, reported its financial results for the three months ended June 30, 2025 ("Q2 2025"), and provided an update on recent corporate developments (Press release, Rakovina Therapeutics, AUG 28, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-three-month-q2-ended-june-30-2025-financial-results-and-provides-corporate-update [SID1234655586]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q2 2025 Financial Highlights
Reported a net loss of $2,916,944.
Research and development (R&D) expenses were $1,611,985, reflecting continued advancement of Al-powered drug candidates.
General and administrative (G&A) expenses were $1,213,489 including investor & public relations and exchange-related fees.
Operating expense cash burn (non-IFRS measure) was approximately $2.65 million.
Cash and cash equivalents as at June 30, 2025 were $1.88 million.
Recent Corporate Highlights
Private Placement Financing: On June 6, 2025, the Company closed a non-brokered private placement of 7,110,300 equity units (71,103,000 pre-consolidation) for gross proceeds of approximately $3.56 million and a concurrent $1.35 million unsecured convertible debenture financing. Each unit consisted of one common share and one warrant exercisable at $1.00 postconsolidation ($0.10 pre-consolidation) for 24 months from the date of issuance.
Reverse Share Consolidation: Effective June 24, 2025, the Company implemented a 1-for-10
share consolidation. Following the consolidation, there were 21,148,039 common shares issued
and outstanding as at June 30, 2025.
Convertible Debentures: During Q2, the Company recorded accretion expense of $38,817 and
issued shares for accrued interest in accordance with the debenture terms.
Subsequent Events
On June 30, 2025, the Company announced its intention to amend certain outstanding warrants and unsecured convertible debentures with an aggregate principal amount of $1.45 million. Amendments remain subject to TSXV approval.
On July 24, 2025, the Company announced a warrant exercise incentive program to encourage early exercise of certain outstanding warrants.
On July 29, 2025, the Company granted 540,000 stock options post-consolidation to consultants, employees, officers, and directors, exercisable at $0.70 per share with a vesting period of six months over three years.
Selected Financial Results for Q2 2025:
June 30, 2025
$ Dec 31, 2024
$
Cash and Cash Equivalents 1,882,886 1,312,743
Working Capital 622,851 321,442
Intangible Assets 3,711,622 3,977,473
Total Assets 6,554,120 6,240,920
Total Liabilities 3,338,110 1,942,005
Deficit (20,076,327) (14,997,929)
Statement of Loss and Comprehensive Loss – Q2 Three months ended June 30
June 30, 2025
$ June 30, 2024
$
Research & Development 1,611,985 479,785
General and Administrative 1,213,489 276,183
Net loss and comprehensive loss (2,916,944) (820,720)
Basic and diluted loss per share (0.18) (0.12)
Operating expense cash burn* 2,653,997 584,535
Weighted average shares outstanding 15,909,657 (post) 7,070,929 (post)
"Operating expense cash burn" = R&D + G&A less non-cash items. This is a non-IFRS measure without a standardized meaning under IFRS.

Rakovina Therapeutics’ financial statements as filed with SEDAR can be accessed from the Company’s website at: View Source

On August 28, 2025 Novocure (NASDAQ: NVCR) reported that management will participate in three upcoming investor events (Press release, NovoCure, AUG 28, 2025, View Source [SID1234655574]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event.
H.C. Wainwright 27th Annual Global Investment Conference, September 9, 2025: Ms. Cordova will take part in a fireside chat at 2:00 p.m. ET, and will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors.
Morgan Stanley 23rd Annual Global Healthcare Conference, September 10, 2025: Ms. Cordova will take part in a fireside chat at 3:20 p.m. ET, and will be joined by Mr. Brackmann for one-on-one meetings with investors.

Live audio webcasts of these presentations can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

On August 28, 2025 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) reported that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma (Press release, Aldeyra Therapeutics, AUG 28, 2025, View Source [SID1234655573]). There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects approximately 100 to 200 people per year in the European Union.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Primary vitreoretinal lymphoma is a potentially fatal cancer that today is treated with off-label compounded formulations of methotrexate that are injected into the eye," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "The receipt of Orphan Designation from the EMA, in conjunction with the previously announced Orphan Drug Designation from the U.S. Food and Drug Administration, is another important step forward for our retinal disease program, complementing our ongoing clinical development of ADX-2191, a novel, vitreous-compatible formulation of methotrexate that is specifically designed for intraocular injection."

A proposed clinical trial, which received Special Protocol Assessment agreement from the U.S. Food and Drug Administration, is designed to compare cancer cell clearance after 30 days of therapy in up to 20 patients following 1:1 randomization to receive either a single intraocular injection or eight intraocular injections of ADX-2191. The frequency of methotrexate injections has been linked to cancer cell clearance in patients with primary vitreoretinal lymphoma,1 and approximately five injections on average has been observed to achieve cancer cell clearance.2 The clinical trial is expected to begin in the second half of 2025 and conclude in 2026.

The EMA grants orphan designation to drugs and biologics intended for the treatment, diagnosis, or prevention of rare, life-threatening, or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan designation allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants, and up to 10 years of market exclusivity in the European Union.

About ADX-2191

ADX-2191 (methotrexate intravitreal injection, USP) is a sterile, non-compounded intravitreal formulation of methotrexate for the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. The ADX-2191 intravitreal formulation is preservative-free, is designed to be vitreous-compatible, and is optimized for excipient composition, viscosity, density, tonicity, pH, concentration, and volume of administration. ADX-2191 received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa, and EMA Orphan Designation for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa, and the treatment of primary large B-cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma.

About Primary Vitreoretinal Lymphoma

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 200 to 600 patients in the United States and 100 to 200 patients in the European Union per year. The median survival for newly diagnosed patients is less than five years. No approved treatments are currently available, though intravitreal injection of compounded methotrexate represents the current standard of care.